Viking Therapeutics has started testing whether tablets of its investigational obesity drug VK2735 can maintain weight loss after an initial course of weekly injections. The company announced the new stage on October 6, 2026.
This is a trial-start announcement, not evidence that a weekly tablet already works. Its practical significance is the question being tested: could a different route or dosing interval maintain the benefit achieved with an initial course of weekly injections?
What changed this week
According to the sponsor announcement, participants first receive weekly injections of VK2735 or placebo for 21 weeks. The subsequent maintenance period evaluates oral and injection regimens through week 33. The oral options include daily and weekly tablets; injection options include every-other-week and monthly dosing. Viking says it expects results in 2027, a forecast rather than a guaranteed reporting date.
VK2735 acts at both GIP and GLP-1 receptors. The experimental maintenance program is separate from the company’s late-stage weekly-injection development program. A molecule can be in a Phase 3 program while a particular route, schedule or maintenance question still needs early-stage investigation. Calling all VK2735 research “Phase 3” would conceal that distinction.
What the registry tells us—and what it does not
The public ClinicalTrials.gov record identifies protocol VK2735-102 as Phase 1. Its listed treatment periods last 21 and 12 weeks, and its arms include a transition from injections to daily or weekly oral treatment. Safety and tolerability are the primary outcome, with measurements of how the body absorbs and clears the drug also specified. That is a reminder to read an exploratory study as a design-and-safety investigation before treating it as a definitive efficacy comparison.
The enrollment figures describe different scopes. Viking’s October announcement plans approximately 195 adults for the new stage; the registry, last updated on September 24, estimates 270 across Parts A and B combined. These are not two competing counts for the same group. Neither adding nor subtracting them establishes the current total: the sources cover different parts of the program and were updated on different dates.
Earlier injection results do not answer the oral question
Viking’s September 22 release reported exploratory maintenance results after participants switched from weekly injections to less frequent injections. Those findings provide a reason to study more options. They do not establish how well a tablet will maintain weight loss, or whether tablet and injection regimens will perform similarly.
There is also a difference between keeping a proportion of previous weight loss and losing that proportion of starting body weight. A maintenance percentage uses the earlier loss as its reference. Readers comparing headlines should check the denominator, follow-up period and analysis population before comparing apparent advantages. Our guide to reading weight-loss trials explains the other design details that can change the interpretation.
Why maintenance deserves its own evidence
A separate randomized study, SURMOUNT-4, helps explain the broader research question. After an initial period on tirzepatide, eligible participants were randomized to continue treatment or switch to placebo. Those who stopped regained substantial weight on average, while continued treatment maintained and extended the initial reduction.
That is evidence about tirzepatide continuation versus withdrawal in the studied population. It cannot predict a VK2735 tablet result, establish a dose-conversion rule, or prove that every person needs the same treatment indefinitely. Different drugs, selection criteria and follow-up periods make informal rankings unreliable. Our withdrawal-trial explainer examines those boundaries in more detail.
What would make the eventual results useful?
The most useful report would make the transition clear: how many people started the initial injection period, known as induction, how many entered each maintenance arm, why others did not continue, and how missing measurements were handled. A treatment can look easier to tolerate after the people who found induction difficult have already left. Reporting only the later participants would not describe the experience of everyone who started.
The duration matters too. A stable average across a short maintenance window cannot establish stability over several years. Readers should look for the pattern over time, individual variation, discontinuation and adverse events—not just the most favorable final average. The actual published comparisons will also matter more than a comparison assembled from unrelated trials.
For now, VK2735 remains an investigational program, and the new oral-maintenance regimens remain unanswered research questions. They are not instructions to space out an existing prescription or switch products. Follow the weight-loss drug evidence hub for established profiles, and bring treatment-change questions to the prescribing team.



